Results 71 to 80 of about 291 (138)

Seminal plasma cfDNA fragmentomics landscape delineates male infertility subtypes

open access: yesClinical Epigenetics
Abstract Background While cell-free DNA (cfDNA) fragmentomics has transformed liquid biopsy applications in prenatal screening and oncology, its potential in male reproductive health remains uncharted. Methods Through integrated whole-genome sequencing and jagged end sequencing (Jag-Seq) coupled with non-CpG methylation analysis, we ...
Wu, Xiaoyu   +4 more
openaire   +2 more sources

Cell-Free DNA Fragmentome Dynamics as a Biomarker for Immune-Checkpoint Inhibition in Advanced Carcinoma

open access: yes
International audienceEarly prediction of resistance to immunotherapy is a major challenge in oncology. The ongoing SChISM (Size Cell-fre DNA (cfDNA) Immunotherapies Signature Monitoring) clinical study proposes an innovative approach based on patented ...
Boutonnet, Audrey   +11 more
core   +1 more source

Next-generation MRD assays: do we have the tools to evaluate them properly?

open access: yes, 2023
Circulating tumour DNA (ctDNA) detection of molecular residual disease (MRD) in solid tumours correlates strongly with patient outcomes and is being adopted as a new clinical standard.
Abbosh, Chris   +8 more
core  

DeepFRAG: a method for cancer detection based on DNA fragmentomics and deep learning

open access: yesBioinformatics Advances
Abstract Motivation Cancer screening using liquid biopsy technology has become standard in modern clinical and preventive oncology. This method analyzes cell-free DNA (cfDNA) circulating in a patient’s bloodstream.
Andrey Koch, Eldar Giladi
openaire   +3 more sources

Cancer‐Like Fragmentomic Characteristics of Somatic Variants in Cell‐Free DNA

open access: yesAdvanced Science
ABSTRACT Cell‐free DNA (cfDNA) in plasma consists of short DNA fragments resulting from a non‐random fragmentation process, with distinct fragmentomic characteristics that are related with their cellular origins. Here, we report that somatic variant signatures in cfDNA markedly differ between non‐cancerous controls and cancer patients,
Zhenyu Zhang   +12 more
openaire   +2 more sources

Circulating cell-free DNA size distribution as a prediction marker for early progression undergoing immune checkpoint inhibitors

open access: yes
International audienceIntroduction: Despite a significant proportion (20 to 40%)[1] of advanced cancer patients having long-term response to treatment with immune checkpoint inhibitors (ICI), many of them do not respond at all and experience early ...
Boutonnet, Audrey   +8 more
core   +3 more sources

pyfraglib : An integrated cfDNA fragmentomics platform

open access: yes
Abstract Summary Cell-free DNA (cfDNA) fragmentomics is the analysis of a diverse set of cfDNA fragment features, e.g. fragment length profiles, windowed protection scores, and end motifs. As such it requires software tooling for fragment extraction, statistical feature modeling,
Daniel Schuette   +5 more
openaire   +1 more source

Sizing and concentration analysis of cfDNA using Biabooster technology: Results from a prospective plasma‐based collection of 77 patients with locally advanced unresectable esophageal cancer

open access: yes
International audienceAbstract Locally advanced esophageal carcinoma remains of poor prognosis correlated with tumor stage. Albeit liquid biopsy approach offers promising results to monitor high‐risk patients in various solid tumors, the lack of specific
Le Sourd, Samuel   +21 more
core   +1 more source

Integrating tumor kinetics and circulating cell-free DNA markers through mechanistic modeling for early prediction of immunotherapy response

open access: yes
International audienceMany cancer patients undergoing immune-checkpoint inhibition (ICI) experience early progression(EP), defined as progression at the first imaging evaluation.
Fina, Frederic   +7 more
core   +1 more source

Home - About - Disclaimer - Privacy